Qinqiao Yanshu Granules
Phase 2Small molecule
Qinqiao Yanshu Granules is one of 28 small molecule programs targeting Pharyngitis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
34 competitors in Pharyngitis
#DrugCompanyPhaseTrials
1Voltaren
NovartisApproved
Bayer Aspirin
BayerApproved
Ketek
SanofiApproved
Biaxin
AbbVieApproved
Anjeso
Boehringer IngelheimApproved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Bextra
TThe Searle Company Limited Pakistan
Approved
Ketalar
AAultman Health Foundation
Approved
Peridex
DDexcel Pharma Technologies Ltd.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Qinqiao Yanshu Granules. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details